Please login to the form below

Not currently logged in
Email:
Password:

Heptares

This page shows the latest Heptares news and features for those working in and with pharma, biotech and healthcare.

Dr Fiona Marshall heads up MSD's new UK research facility

Dr Fiona Marshall heads up MSD's new UK research facility

Dr Marshall joins the new venture from Sosei Group Corporation, where she was executive vice president and chief scientific officer, and she also co-founded Heptares Therapeutics, a biotechnology company, which ... Prior to Heptares, Dr Marshall spent 12

Latest news

  • Pfizer signs high-level deal with GPCR specialist Heptares Pfizer signs high-level deal with GPCR specialist Heptares

    Pfizer signs high-level deal with GPCR specialist Heptares. Wide-rangingdeal will involve up to 10 drug targets. ... biologics drugs - and will pay up to $189m per project to Heptares as well as an undisclosed upfront payment.

  • Teva buys into Heptares oral CGRP programme for migraine Teva buys into Heptares oral CGRP programme for migraine

    Teva buys into Heptares oral CGRP programme for migraine. Signs$410m alliance for early-stage candidates in potentially-lucrative drug class. ... Teva will co-develop Heptares Pharma's portfolio of migraine therapies in a new alliance valued at up to

  • AZ adds cancer vaccine to immuno-oncology portfolio AZ adds cancer vaccine to immuno-oncology portfolio

    The agreement comes hard on the heels of two other deals signed by AZ last week with Heptares and Mirati, which in turn extended a lengthening list of collaborations designed to

  • AZ signs two more deals in cancer immunotherapy AZ signs two more deals in cancer immunotherapy

    AZ signs two more deals in cancer immunotherapy. Anglo-Swedish firm pens partnerships with Heptares and Mirati Therapeutics. ... AstraZeneca continues to push its immuno-oncology programme hard, signing two new deals this week with Heptares and Mirati

  • Pharma deals for March 2012 Pharma deals for March 2012

    Shire also kept the news flow running from last month with a further two transactions – the exercise of its option with Heptares and also the acquisition of FerroKin BioSciences for an ... 270. Heptares / Shire. Exclusive worldwide licence. Exercise of

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    rights to Heptares’G protein-coupled receptor product for pain relief. ... 20. Heptares/ Sosei Group. Daiichi Sankyo. Licence. G protein coupled receptor for pain relief.

  • Deal Watch April 2016 Deal Watch April 2016

    Allergan must have known for some time that the Pfizer acquisition was likely to collapse because on the same day as the announcement, Allergan announced a $3.3bn deal with Heptares ... 9, 800. Heptares (JP). Allergan (IE). License and collaboration.

  • Deal Watch November 2015 Deal Watch November 2015

    455. Heptares. Teva. Licence drug-discovery agreement. Small molecule calcitonin gene-related peptide (CGRP) antagonists for migraine. ... 225. Heptares. Pfizer. Strategic discovery collaboration. New therapeutics against up to 10 GPCR targets across

  • Pharma deals in August 2015 Pharma deals in August 2015

    AstraZeneca deals. Subject. Headline $m. Inovio. Cancer vaccines. 727. Heptares. HTL 1071 and A2A receptor blocking compounds. ... The deal brings an upfront of $10m to Heptares with a further $500m and tiered double digit royalties.

  • Pharma deals in February 2015 Pharma deals in February 2015

    Heptares has fine-tuned the approach designing improved, stabilised drugs building on an in-depth understanding of the structure of receptors, and structure-based drug design employing the proprietary StaR technology ... Heptares will become a wholly

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Metrion Biosciences adds to its board Metrion Biosciences adds to its board

    Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.

  • Sosei appoints chief operating officer Sosei appoints chief operating officer

    He has served as a non-executive director at Sosei since 2010, and has since worked at Syngene International, where he was chief executive and executive director, and Heptares Therapeutics, where

  • Former Amgen EVP Roger Perlmutter joins Heptares board Former Amgen EVP Roger Perlmutter joins Heptares board

    Former Amgen EVP Roger Perlmutter joins Heptares board. Also has experience at Merck &Co. ... Heptares has appointed Amgen's former executive VP, R&D, Dr Roger Perlmutter, to its board of directors.

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics